Mar 14, 2022 / 12:00PM GMT
Operator
Good morning, ladies and gentlemen, and welcome to the Phase III PaTHway Trial Results Conference Call. (Operator Instructions). As a reminder, this conference call is being recorded.
I would now like to turn the conference over to your host, Tim Lee, Senior Director of Investor Relations. Please go ahead.
Timothy Lee;Senior Director of Investor Relations -
Yes. Thank you, operator, and thanks, everyone, for joining our Phase III PaTHway Trial Results Conference Call today. I'm Tim Lee, Senior Director, Investor Relations, of Ascendis Pharma.
As part of today's webcast, we have an accompanying slide deck available for download that you can follow on our Investor Relations website. Joining me on today's call is Jan Mikkelsen, President and Chief Executive Officer; Dr. Aimee Shu, Vice President, Clinical Development Endocrine Medical Science; Dr. Dana Pizzuti, Head of Development, Operations and Chief Medical -- Head of Development, Operations and Chief Medical Officer; and Scott Smith, Senior Vice President and Chief Financial Officer.
Ascendis Pharma A/S Announces Phase 3 PaTHway Trial Results Conference Call Transcript
Mar 14, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers